These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2560915)

  • 1. In vitro neutralization of antigenic variants of bluetongue virus is related to in vivo protection.
    Sundin DR; Dean VC; DuBard KM; Mecham JO
    Viral Immunol; 1989; 2(3):195-203. PubMed ID: 2560915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformationally dependent epitopes of bluetongue virus neutralizing antigen.
    Grieder FB; Schultz KT
    Viral Immunol; 1989; 2(1):17-24. PubMed ID: 2472808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies to bluetongue virus define two neutralizing epitopes and a hemagglutinating epitope.
    Mecham JO; Jochim MM
    Viral Immunol; 1990; 3(2):161-70. PubMed ID: 1694430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory evaluation of a living attenuated vaccine against bluetongue type 20 virus.
    Wark MC; Shepherd-Clark MB; Smith HV; Collins WD
    Aust Vet J; 1982 Jul; 59(1):6-10. PubMed ID: 6293439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of neutralising antibody in passive immunity to bluetongue infection.
    Jeggo MH; Wardley RC; Taylor WP
    Res Vet Sci; 1984 Jan; 36(1):81-6. PubMed ID: 6324311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic response of sheep to inactivated and virulent bluetongue virus.
    Stott JL; Barber TL; Osburn BI
    Am J Vet Res; 1985 May; 46(5):1043-9. PubMed ID: 2988376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformation of the VP2 protein of bluetongue virus (BTV) determines the involvement in virus neutralization of highly conserved epitopes within the BTV serogroup.
    White JR; Eaton BT
    J Gen Virol; 1990 Jun; 71 ( Pt 6)():1325-32. PubMed ID: 1693664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of four distinct neutralizing epitopes on bluetongue virus serotype 10 using neutralizing monoclonal antibodies and neutralization-escape variants.
    Heidner HW; Rossitto PV; MacLachlan NJ
    Virology; 1990 Jun; 176(2):658-61. PubMed ID: 1693250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and serological response of sheep to serial challenge with different bluetongue virus types.
    Jeggo MH; Gumm ID; Taylor WP
    Res Vet Sci; 1983 Mar; 34(2):205-11. PubMed ID: 6304836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potency and efficacy of inactivated bluetongue virus vaccines.
    Stevens DR; Stott J; Osburn BI; Giles R; Wiesehahn GP; Barber TL
    Prog Clin Biol Res; 1985; 178():649-52. PubMed ID: 2989914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of neutralization-related epitopes within a bluetongue virus serotype.
    Letchworth GJ; Appleton JA
    Virology; 1983 Jan; 124(2):300-7. PubMed ID: 6186077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
    Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
    Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody analysis of serotype-restricted and unrestricted bluetongue viral antigenic determinants.
    Appleton JA; Letchworth GJ
    Virology; 1983 Jan; 124(2):286-99. PubMed ID: 6186076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep.
    Oura CA; Wood JL; Sanders AJ; Bin-Tarif A; Henstock M; Edwards L; Floyd T; Simmons H; Batten CA
    Vaccine; 2009 Dec; 27(52):7326-30. PubMed ID: 19786141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A complex neutralization domain of bluetongue virus serotype 17 defines a virulence-associated marker.
    Bernard KA; Israel BA; Schultz KT
    Viral Immunol; 1996; 9(2):97-106. PubMed ID: 8822626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An experimental inactivated vaccine against bluetongue.
    Parker J; Herniman KA; Gibbs EP; Sellers RF
    Vet Rec; 1975 Mar; 96(13):284-7. PubMed ID: 165609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep.
    Huismans H; van der Walt NT; Cloete M; Erasmus BJ
    Virology; 1987 Mar; 157(1):172-9. PubMed ID: 3029956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bluetongue vaccine: cells and/or antibodies.
    Jeggo MH; Wardley RC
    Vaccine; 1985 Mar; 3(1):57-8. PubMed ID: 2988227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemical analyses of Australian bluetongue virus serotypes using monoclonal antibodies.
    White JR; Breschkin AM; Della-Porta AJ
    Prog Clin Biol Res; 1985; 178():397-405. PubMed ID: 2989877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of recombinant DNA technology for the development of a bluetongue virus subunit vaccine.
    Huismans H
    Onderstepoort J Vet Res; 1985 Sep; 52(3):149-51. PubMed ID: 3003649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.